The U.S. Food and Drug Administration (FDA) has recently granted regulatory approval to
a new device that allows patients with osteoporosis to
quickly determine whether their treatment is working. Patients use a hand-held disposable
device called the Osteomark NTx Point-of-Care to measure their bone loss (bone resorption
changes) to make sure they are not losing too much bone. Prior to the FDAs recent
regulatory approval, the device was only available in physician offices. Now, the
manufacturer expects to make the device available by prescription to osteoporosis patients
later this year.
Osteoporosis is a degenerative bone disease that primarily affects post-menopausal
women. It is estimated that one in two women over 50 will have an osteoporosis-related
fracture. Literally meaning "porous bone," osteoporosis is characterized by a
decrease in normal bone density due to the loss of calcium and collagen. A loss of bone
density causes bones to become brittle, and in turn, leads to frequent fractures and other
serious effects. There are several options available to help prevent or treat osteoporosis
in patients with low bone density. These include hormone
replacement therapy, and other drugs such as Fosamax (generic name, alendronate), Evista (raloxifene), Actonel (risedronate sodium), and Miacalcin (calcitonin).
Patients with or at risk for osteoporosis are diagnosed with bone mineral density tests
at their physicians office with x-rays (such as DEXA),
CT scans (Osteo CT or QCT) and/or ultrasound. If patients are found to have low bone
mineral density, they are usually advised to begin treatment with medications and/or
maintain a diet rich in calcium and vitamin D. All women 65 years of age and older should
have a bone mineral density test and younger women with one or more risk factors for
osteoporosis may also need the test. Only a bone mineral density test can determine
whether a patient is at risk for a fracture and osteoporosis.
The new at-home device can help patients with osteoporosis learn whether their
treatment is working or whether they may need to change to another treatment. The
single-use test, which will be available in the near future at U.S. pharmacies by
prescription, will retail for approximately $38, according to its manufacturer, Ostex
International, Inc.
The device measures the level of a protein fragment called NTx which is a byproduct of
bone matter found in the urine. By determining the amount of NTx in the urine, patients
will be able to learn if they are losing too much bone. Physicians and instructions
included with the device will help patients learn how to use the test and interpret the
results. Results are available within five minutes of use and can be used within three
months after treatment has begun. Proctor & Gamble has been using the device in Europe
in clinical trials of its osteoporosis drug Actonel, a
drug used to prevent or treat osteoporosis.
Osteoporosis is a threat to 28 million Americans and is currently one of the most
under-diagnosed and under-treated disorders in medicine. An estimated 1.5 million
fractures can be attributed to osteoporosis each year.
Risk factors for osteoporosis include:
- Female gender
- Advancing age, especially the onset of menopause
- Race (Asian and Caucasian)
- Thin build or small body frame
- Low calcium intake
- Lack of physical activity
- History of broken bones
- Certain diseases such as diabetes and kidney or liver diseases
Click here for a full list and
explanation of risk factors for osteoporosis.
Additional Resources and References
Back to Osteoporosis News Menu |